[Effect of plasmapheresis in kidney transplantation--a controlled study].
Until recently it has been controversial whether plasmapheresis is benefitial in graft rejection therapy. Here we present a controlled trial in 44 kidney transplanted patients with biopsy proven acute vascular rejection and specific anti-HLA-antibodies. 23 randomized patients were treated additionally with plasmaexchange (group A), whereas the remaining 21 received drug therapy only (group B). 7 out of 23 (30%) lost their graft in group A and 17 out of 21 (81%) in group B. Mean serum creatinine and actuarial graft survival underline the significant effect of plasmaexchange therapy which appears especially benefitial when rejection occurs later than one month after surgery.
D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000187:drug effects; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D007677:Kidney Function Tests; D016030:Kidney Transplantation; D008775:Methylprednisolone / Q000627:therapeutic use; D010951:Plasma Exchange; D010956:Plasmapheresis; D011183:Postoperative Complications / Q000628:therapy*; D011897:Random Allocation
D000961:Antilymphocyte Serum; D006680:HLA Antigens; D003520:Cyclophosphamide; D003404:Creatinine; D001379:Azathioprine; D008775:Methylprednisolone
Wirkung der Plasmapherese bei Nierentransplantation--eine kontrollierte Studie.